Metformin adherence and the risk of cardiovascular disease: a population-based cohort study

CONCLUSIONS: This study revealed that metformin adherence in patients with T2DM who required a first-line treatment may reduce the risk of subsequent CVD. Despite the availability of numerous novel antiglycemic agents, metformin adherence by patients who require a combination of antiglycemic agents provides an additional benefit of CVD protection.PMID:37051071 | PMC:PMC10084537 | DOI:10.1177/20406223231163115
Source: Adv Data - Category: Epidemiology Authors: Source Type: research